Coradini Danila, Biganzoli Elia, Ardoino Ilaria, Ambrogi Federico, Boracchi Patrizia, Demicheli Romano, Daidone Maria Grazia, Moliterni Angela
Unit of Medical Statistics, Biometry and Bioinformatics "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Unit of Medical Statistics, Biometry and Bioinformatics "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Breast. 2015 Jun;24(3):294-7. doi: 10.1016/j.breast.2015.01.007. Epub 2015 Feb 16.
Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes. Based on this finding, we explored the contribution of p53 status in predicting the response to adjuvant CMF or CMF followed doxorubicin chemotherapy of a group of TNBC patients. Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overall survival than patients carrying a p53-negative TNBC, corroborating our hypothesis about the relationship between TNBC phenotype (basal-like versus normal-like) and p53 status as predictor of response to anthracycline/CMF-based chemotherapy.
基因组分析和蛋白质表达显示三阴性乳腺癌（TNBC）与基底样乳腺肿瘤相似。然而，事实证明TNBC也包括具有正常样表型的肿瘤，这些肿瘤预后良好且对化疗有反应。在最近的一篇论文中，我们提供了证据表明p53状态能够将TNBC细分为两个具有不同预后的不同亚组，且与基底样和正常样表型一致。基于这一发现，我们探讨了p53状态在预测一组TNBC患者对辅助CMF或CMF序贯阿霉素化疗反应中的作用。结果表明，p53阳性肿瘤的TNBC患者无复发生存期和总生存期比携带p53阴性TNBC的患者短，证实了我们关于TNBC表型（基底样与正常样）与p53状态之间关系的假设，即p53状态可作为基于蒽环类/CMF化疗反应的预测指标。
